Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGFR | P00533 | 10/20 | 0.82 |
| ▸ | ERBB2 | P04626 | 1/20 | 0.82 |
| ▸ | MEN1 | O00255 | 9/20 | 0.64 |
| ▸ | KMT2A | Q03164 | 9/20 | 0.64 |
| ▸ | ALDH1A1 | P00352 | 9/20 | 0.64 |
| ▸ | MAPT | P10636 | 9/20 | 0.64 |
| ▸ | HPGD | P15428 | 6/20 | 0.64 |
| ▸ | LMNA | P02545 | 5/20 | 0.64 |
| ▸ | CYP3A4 | P08684 | 5/20 | 0.64 |
| ▸ | NFKB1 | P19838 | 5/20 | 0.64 |
| ▸ | BLM | P54132 | 5/20 | 0.64 |
| ▸ | PMP22 | Q01453 | 5/20 | 0.64 |
| ▸ | KDM4E | B2RXH2 | 5/20 | 0.64 |
| ▸ | CYP2C9 | P11712 | 4/20 | 0.64 |
| ▸ | ALOX15 | P16050 | 4/20 | 0.64 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.64 |
| ▸ | HIF1A | Q16665 | 4/20 | 0.64 |
| ▸ | HSD17B10 | Q99714 | 4/20 | 0.64 |
| ▸ | NPSR1 | Q6W5P4 | 4/20 | 0.64 |
| ▸ | TSHR | P16473 | 4/20 | 0.64 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10186359 | 0.90 | EGFR (1.00) | EGFRERBB2MEN1KMT2AALDH1A1 | |
| SCHEMBL10186365 | 0.87 | EGFR (0.70) | EGFRERBB2MEN1KMT2AALDH1A1 | |
| SCHEMBL10241929 | 0.79 | EGFR (0.70) | EGFRERBB2MEN1KMT2AALDH1A1 | |
| Tyrphostin 25 SCHEMBL239879 | 0.78 | EGFR (1.00) | EGFRERBB2MEN1KMT2AALDH1A1 | |
| SCHEMBL17466923 | 0.78 | ALDH1A1 (0.61) | EGFRERBB2MEN1KMT2AALDH1A1 | |
| SCHEMBL12546881 | 0.77 | EGFR (0.57) | EGFRERBB2MEN1KMT2AALDH1A1 | |
| SCHEMBL15370274 | 0.77 | EGFR (0.57) | EGFRERBB2MEN1KMT2AALDH1A1 | |
| SCHEMBL5363574 | 0.76 | EGFR (0.61) | EGFRERBB2MEN1KMT2AALDH1A1 | |
| SCHEMBL14532648 | 0.76 | EGFR (0.61) | EGFRERBB2MEN1KMT2AALDH1A1 | |
| SCHEMBL8609619 | 0.76 | EGFR (1.00) | EGFRERBB2MEN1KMT2AALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 34 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4483376-A1 | MEASUREMENT, DIAGNOSIS, TREATMENT AND MANAGEMENT OF METABOLIC SYNDROME | García Sada, Fernando (MX) | 2025-01-01 | — | — | EP | claimed |
| US-20240374552-A1 | Compositions and Methods for Preventing or Reducing the Risk of Metabolic Syndrome | GARCÍA SADA, FERNANDO (MX) | 2024-11-14 | — | — | US | claimed |
| CN-118922890-A | Measurement, diagnosis, treatment and management of metabolic syndrome | 费尔南多·加西亚·萨达 | 2024-11-08 | — | — | CN | claimed |
| EP-4393486-A1 | COMPOSITIONS AND METHODS FOR PREVENTING OR REDUCING THE RISK OF METABOLIC SYNDROME | García Sada, Fernando (MX) | 2024-07-03 | — | — | EP | claimed |
| WO-2023161832-A1 | MEASUREMENT, DIAGNOSIS, TREATMENT AND MANAGEMENT OF METABOLIC SYNDROME | GARCIA SADA FERNANDO (MX) | 2023-08-31 | — | — | WO | claimed |
| US-20230266340-A1 | Measurement, Diagnosis, Treatment and Management of Metabolic Syndrome | SILTI AG (CH) | 2023-08-24 | — | — | US | claimed |
| WO-2023027570-A1 | COMPOSITIONS AND METHODS FOR PREVENTING OR REDUCING THE RISK OF METABOLIC SYNDROME | GARCÍA SADA, FERNANDO (MX) | 2023-03-02 | — | — | WO | claimed |
| EP-4483376-A1 | MEASUREMENT, DIAGNOSIS, TREATMENT AND MANAGEMENT OF METABOLIC SYNDROME | García Sada, Fernando (MX) | 2025-01-01 | — | — | EP | disclosed |
| US-20240374552-A1 | Compositions and Methods for Preventing or Reducing the Risk of Metabolic Syndrome | GARCÍA SADA, FERNANDO (MX) | 2024-11-14 | — | — | US | disclosed |
| US-20240374552-A1 | Compositions and Methods for Preventing or Reducing the Risk of Metabolic Syndrome | GARCÍA SADA, FERNANDO (MX) | 2024-11-14 | — | — | US | disclosed |
| CN-118922890-A | Measurement, diagnosis, treatment and management of metabolic syndrome | 费尔南多·加西亚·萨达 | 2024-11-08 | — | — | CN | disclosed |
| EP-4393486-A1 | COMPOSITIONS AND METHODS FOR PREVENTING OR REDUCING THE RISK OF METABOLIC SYNDROME | García Sada, Fernando (MX) | 2024-07-03 | — | — | EP | disclosed |
| EP-4393486-A1 | COMPOSITIONS AND METHODS FOR PREVENTING OR REDUCING THE RISK OF METABOLIC SYNDROME | García Sada, Fernando (MX) | 2024-07-03 | — | — | EP | disclosed |
| US-20160000745-A1 | METHODS AND COMPOSITIONS FOR TREATING OBESITY, PREVENTING WEIGHT GAIN, PROMOTING WEIGHT LOSS, PROMOTING SLIMMING, OR TREATING OR PREVENTING THE DEVELOPMENT OF DIABETES | MOLECULE X LLC | 2016-01-07 | — | — | US | disclosed |
| US-20160000745-A1 | METHODS AND COMPOSITIONS FOR TREATING OBESITY, PREVENTING WEIGHT GAIN, PROMOTING WEIGHT LOSS, PROMOTING SLIMMING, OR TREATING OR PREVENTING THE DEVELOPMENT OF DIABETES | MOLECULE X LLC | 2016-01-07 | — | — | US | disclosed |
| US-20160000745-A1 | METHODS AND COMPOSITIONS FOR TREATING OBESITY, PREVENTING WEIGHT GAIN, PROMOTING WEIGHT LOSS, PROMOTING SLIMMING, OR TREATING OR PREVENTING THE DEVELOPMENT OF DIABETES | MOLECULE X LLC | 2016-01-07 | — | — | US | disclosed |
| EP-1575575-B1 | SAFE CHEMICAL UNCOUPLERS FOR THE TREATMENT OF OBESITY | HIGH POINT PHARMACEUTICALS LLC (US) | 2010-05-19 | — | — | EP | disclosed |
| EP-1575575-A2 | SAFE CHEMICAL UNCOUPLERS FOR THE TREATMENT OF OBESITY | NOVO NORDISK A/S (DK) | 2005-09-21 | — | — | EP | disclosed |
| US-20040138301-A1 | Chemical uncouplers for the treatment of obesity | HIGH POINT PHARMACEUTICALS, LLC | 2004-07-15 | — | — | US | disclosed |
| WO-2004041256-A2 | SAFE CHEMICAL UNCOUPLERS FOR THE TREATMENT OF OBESITY | NOVO NORDISK A/S (DK) | 2004-05-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240374552-A1 | Compositions and Methods for Preventing or Reducing the Risk of Metabolic Syndrome | GPR119, GPR27, PTPN7 | EGFR 565/4885ERBB2 298/4885MEN1 2509/4885 |
| US-20160000745-A1 | METHODS AND COMPOSITIONS FOR TREATING OBESITY, PREVENTING WEIGHT GAIN, PROMOTING WEIGHT LOSS, PROMOTING SLIMMING, OR TREATING OR PREVENTING THE DEVELOPMENT OF DIABETES | GPR119, CPT1B, CPT2 | EGFR 3356/4885ERBB2 1455/4885MEN1 3979/4885 |
| US-20040138301-A1 | Chemical uncouplers for the treatment of obesity | PC, CPT2, IDH2 | EGFR 2998/4885ERBB2 857/4885MEN1 3305/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.